Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
≥1 32 34 32 34 O
x 35 36 35 36 I-lower_bound
10 37 39 37 39 I-lower_bound
^ 39 40 39 40 I-lower_bound
9 40 41 40 41 I-lower_bound
/ 41 42 41 42 I-lower_bound
L 42 43 42 43 I-lower_bound

Allogeneic 0 10 44 54 B-treatment
stem 11 15 55 59 I-treatment
cell 16 20 60 64 I-treatment
transplantation 21 36 65 80 I-treatment

Eastern 0 7 81 88 B-clinical_variable
Cooperative 8 19 89 100 I-clinical_variable
Oncology 20 28 101 109 I-clinical_variable
Group 29 34 110 115 I-clinical_variable
( 35 36 116 117 I-clinical_variable
ECOG 36 40 117 121 I-clinical_variable
) 40 41 121 122 I-clinical_variable
performance 42 53 123 134 I-clinical_variable
status 54 60 135 141 I-clinical_variable
≤1 61 63 142 144 O

Have 0 4 145 149 O
documented 5 15 150 160 O
CD20 16 20 161 165 O
+ 20 21 165 166 O
B 22 23 167 168 O
- 23 24 168 169 O
cell 24 28 169 173 O
malignancy 29 39 174 184 B-cancer
, 39 40 184 185 O
with 41 45 186 190 O
active 46 52 191 197 O
disease 53 60 198 205 O
not 61 64 206 209 O
responsive 65 75 210 220 O
to 76 78 221 223 O
prior 79 84 224 229 B-treatment
therapy 85 92 230 237 I-treatment
, 92 93 237 238 O
for 94 97 239 242 O
whom 98 102 243 247 O
no 103 105 248 250 O
standard 106 114 251 259 O
of 115 117 260 262 O
care 118 122 263 267 O
options 123 130 268 275 O
exists 131 137 276 282 O
, 137 138 282 283 O
and 139 142 284 287 O
for 143 146 288 291 O
whom 147 151 292 296 O
treatment 152 161 297 306 B-treatment
with 162 166 307 311 O
an 167 169 312 314 O
anti 170 174 315 319 B-treatment
- 174 175 319 320 I-treatment
CD20 175 179 320 324 I-treatment
antibody 180 188 325 333 I-treatment

Hb 0 2 334 336 B-clinical_variable
level 3 8 337 342 I-clinical_variable
≥9 9 11 343 345 O
g 12 13 346 347 I-lower_bound
/ 13 14 347 348 I-lower_bound
dL 14 16 348 350 I-lower_bound

History 0 7 351 358 O
of 8 10 359 361 O
hypersensitivity 11 27 362 378 O
to 28 30 379 381 O
any 31 34 382 385 O
compound 35 43 386 394 O
in 44 46 395 397 O
the 47 50 398 401 O
tetracycline 51 63 402 414 B-allergy_name
antibiotics 64 75 415 426 O
group 76 81 427 432 O

History 0 7 433 440 O
of 8 10 441 443 O
or 11 13 444 446 O
current 14 21 447 454 O
relevant 22 30 455 463 O
CNS 31 34 464 467 B-chronic_disease
pathology 35 44 468 477 O

Infection 0 9 478 487 O
with 10 14 488 492 O
human 15 20 493 498 B-chronic_disease
immunodeficiency 21 37 499 515 I-chronic_disease
virus 38 43 516 521 I-chronic_disease
( 44 45 522 523 I-chronic_disease
HIV 45 48 523 526 I-chronic_disease
) 48 49 526 527 I-chronic_disease
or 50 52 528 530 O
chronic 53 60 531 538 B-chronic_disease
infection 61 70 539 548 I-chronic_disease
with 71 75 549 553 O
hepatitis 76 85 554 563 B-chronic_disease
B 86 87 564 565 I-chronic_disease
virus 88 93 566 571 I-chronic_disease
( 94 95 572 573 I-chronic_disease
HBV 95 98 573 576 I-chronic_disease
) 98 99 576 577 I-chronic_disease
or 100 102 578 580 O
hepatitis 103 112 581 590 B-chronic_disease
C 113 114 591 592 I-chronic_disease
virus 115 120 593 598 I-chronic_disease
( 121 122 599 600 I-chronic_disease
HCV 122 125 600 603 I-chronic_disease
) 125 126 603 604 I-chronic_disease

Known 0 5 605 610 O
hypersensitivity 6 22 611 627 O
to 23 25 628 630 O
both 26 30 631 635 O
allopurinol 31 42 636 647 B-allergy_name
and 43 46 648 651 O
rasburicase 47 58 652 663 B-allergy_name

Life 0 4 664 668 B-clinical_variable
expectancy 5 15 669 679 I-clinical_variable
of 16 18 680 682 O
at 19 21 683 685 O
least 22 27 686 691 O
6 28 29 692 693 B-lower_bound
months 30 36 694 700 I-lower_bound

Must 0 4 701 705 O
have 5 9 706 710 O
at 10 12 711 713 O
least 13 18 714 719 O
one 19 22 720 723 B-lower_bound
bi 23 25 724 726 O
- 25 26 726 727 O
dimensionally 26 39 727 740 O
measurable 40 50 741 751 O
lesion 51 57 752 758 B-clinical_variable
≥1.5 58 62 759 763 O
cm 63 65 764 766 I-lower_bound
) 65 66 766 767 O
documented 67 77 768 778 O
by 78 80 779 781 O
CT 81 83 782 784 B-treatment
scan 84 88 785 789 I-treatment

NHL 0 3 790 793 B-cancer
patients 4 12 794 802 O
must 13 17 803 807 O
have 18 22 808 812 O
had 23 26 813 816 O
prior 27 32 817 822 B-treatment
treatment 33 42 823 832 I-treatment
with 43 47 833 837 O
an 48 50 838 840 O
anti 51 55 841 845 B-treatment
- 55 56 845 846 I-treatment
CD20 56 60 846 850 I-treatment
antibody 61 69 851 859 I-treatment
therapy 70 77 860 867 I-treatment

Platelet 0 8 868 876 B-clinical_variable
counts 9 15 877 883 I-clinical_variable
≥75 16 19 884 887 O
x 20 21 888 889 I-lower_bound
10 22 24 890 892 I-lower_bound
^ 24 25 892 893 I-lower_bound
9 25 26 893 894 I-lower_bound
/ 26 27 894 895 I-lower_bound
L 27 28 895 896 I-lower_bound

Primary 0 7 897 904 B-cancer
central 8 15 905 912 I-cancer
nervous 16 23 913 920 I-cancer
system 24 30 921 927 I-cancer
( 31 32 928 929 I-cancer
CNS 32 35 929 932 I-cancer
) 35 36 932 933 I-cancer
lymphoma 37 45 934 942 I-cancer
or 46 48 943 945 O
known 49 54 946 951 O
or 55 57 952 954 O
suspected 58 67 955 964 O
CNS 68 71 965 968 B-cancer
involvement 72 83 969 980 I-cancer
by 84 86 981 983 I-cancer
non 87 90 984 987 I-cancer
- 90 91 987 988 I-cancer
primary 91 98 988 995 I-cancer
CNS 99 102 996 999 I-cancer
NHL 103 106 1000 1003 I-cancer

